Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of an efficacy of eplerenone combined therapy for hypertensive patients with chronic kidney disease that enough hypotensive effect are not obtained with an angiotensin receptor blocker

Next Previous
Trial Profile

Investigation of an efficacy of eplerenone combined therapy for hypertensive patients with chronic kidney disease that enough hypotensive effect are not obtained with an angiotensin receptor blocker

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplerenone (Primary) ; Hydrochlorothiazide; Trichlormethiazide
  • Indications Hypertension; Renal failure
  • Focus Therapeutic Use
  • Acronyms OWASE

Most Recent Events

  • 28 Aug 2017 Primary endpoint (Mean percent change in UACR) has not been met, according to the results published in the Journal of Clinical Hypertension (Greenwich).
  • 28 Aug 2017 Results published in the Journal of Clinical Hypertension (Greenwich)
  • 29 Sep 2016 Results of subanalysis (n=68) presented at the 26th Scientific Meeting of the International Society of Hypertension

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top